Romano Abuaba, MD
Internal Medicine · Aurora, CONPI 1295014710
Payments from drug & device makers
Across 87 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$341
- Sumitomo Pharma America, Inc.$163
- Novo Nordisk$124
- Neurocrine Biosciences, Inc.$106
- Acadia Pharmaceuticals Inc$103
- Lilly USA, LLC$103
- plus $729 from 19 others
What the payments were for
- Food & beverage$1,669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $341 |
| Sumitomo Pharma America, Inc. | 8 | $163 |
| Novo Nordisk | 7 | $124 |
| Neurocrine Biosciences, Inc. | 5 | $106 |
| Acadia Pharmaceuticals Inc | 4 | $103 |
| Lilly USA, LLC | 6 | $103 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| AbbVie(2 entities) | 4 | $83 |
| Merck | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Dexcom, Inc. | 2 | $49 |
| Novartis | 3 | $49 |
| Lundbeck LLC | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $41 |
| Pfizer | 2 | $41 |
| Astellas Pharma US Inc | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Amgen | 1 | $20 |
| Nevro Corp. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,669 in reported general payments places this provider in the 85th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 749 | $288,044 |
| TrulicityDulaglutide | 81 | $78,489 |
| OrenciaAbatacept | 11 | $62,969 |
| MounjaroTirzepatide | 40 | $51,870 |
| XareltoRivaroxaban | 112 | $48,826 |
| JardianceEmpagliflozin | 122 | $47,952 |
| MyrbetriqMirabegron | 162 | $47,622 |
| TradjentaLinagliptin | 160 | $44,792 |
| Spiriva HandihalerTiotropium Bromide | 66 | $38,442 |
| OzempicSemaglutide | 27 | $35,232 |
| RytaryCarbidopa/Levodopa | 49 | $34,360 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $25,263 |
| FarxigaDapagliflozin Propanediol | 24 | $24,590 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $23,993 |
| LinzessLinaclotide | 25 | $21,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $41 | $298,712782 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $103 | $130,359121 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat | $11 | $115,074313 claims |
| Johnson & JohnsonXarelto | $341 | $48,826112 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $47,622162 claims |
| Novo NordiskOzempic | $124 | $35,23227 claims |
| AbbVieLinzess, Combigan | $83 | $25,57542 claims |
| NovartisEntresto | $49 | $15,45645 claims |
| MerckJanuvia | $74 | $5,72612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Aurora
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Kristine KuhnAurora$400K
- Kelsey FlintAurora$244K
- Paul Menard-KatcherAurora$203K
- Robert DoolanAurora$143K
- Cherry DelosreyesAurora$15K
- Shabana JiwaniAurora$10K
- Shahzaib NabiAurora$10K
- Stanton ElziWheat Ridge$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.